Last reviewed · How we verify
BEY2153
BEY2153 is a small molecule that targets the PI3K pathway.
BEY2153 is a small molecule that targets the PI3K pathway. Used for Metastatic breast cancer.
At a glance
| Generic name | BEY2153 |
|---|---|
| Sponsor | BeyondBio Inc. |
| Drug class | PI3K inhibitor |
| Target | PI3K |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
It works by inhibiting the activity of PI3K, which is involved in cell signaling and proliferation. This inhibition can lead to anti-tumor effects.
Approved indications
- Metastatic breast cancer
Common side effects
- Diarrhea
- Nausea
- Fatigue
Key clinical trials
- A Phase 2 Study to Evaluate the Safety and Efficacy of BEY2153 in Patients with Early Alzheimer's Disease (PHASE2)
- A Study to Evaluate the Pharmacokinetics and Safety of BEY2153 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |